Tag: record

FREEHOLD, NJ, July 02, 2025 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in the ownership and operation of manufactured home communities, is providing investors with an update on the second quarter of 2025 operating results:

Annual Developer Conference Hosts Major Semiconductor Companies for Dialogue on Latest Test Technologies and Industry Trends

RENAULT GROUP: EMPLOYEE SHARE OWNERSHIP, A SUSTAINED COMMITMENT

RENAULT GROUP : L’ACTIONNARIAT SALARIÉ, UN ENGAGEMENT QUI S’ANCRE DURABLEMENT 

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sable Offshore Corp. (NYSE: SOC), including those who purchased shares pursuant to Sable Offshore Corp.’s May 2025 public offering, resulting from allegations that Sable Offshore Corp. may have issued materially misleading business information to the investing public.

FREEHOLD, NJ, July 01, 2025 (GLOBE NEWSWIRE) -- On July 1, 2025, the Board of Directors of UMH Properties, Inc. (NYSE: UMH) (TASE: UMH) declared its quarterly cash dividend on the Company’s Common Stock of $0.225 per share payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025. The Company’s annual dividend rate on its Common Stock is $0.90 per share.

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) --

Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Sage Therapeutics, Inc. (NASDAQ: SAGE) related to its sale to Supernus Pharmaceuticals, Inc. Upon completion of the proposed transaction, current Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable (i) $0.50 the first commercial sale of the drug Zurzuvae in Japan to third-aprty consumers following regulatory approval on or before June 30, 2026; (ii) $1.00 when net sales of Zurzuvae reach or exceed $300 million in the U.S. on or before December 31, 2028; and (iii) $1.00 when net sales of Zurzuvae reach or exceed $375 million in the U.S. on or before December 31, 2030. Is it a fair deal?

  Trusted Gold Experts Provide Families with Secure, Diversified Investment Solutions for a Stronger Tomorrow